These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 30282880)
1. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. Miyazawa T; Marushima H; Saji H; Kojima K; Hoshikawa M; Takagi M; Nakamura H Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):1-9. PubMed ID: 30282880 [TBL] [Abstract][Full Text] [Related]
2. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548 [No Abstract] [Full Text] [Related]
3. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1. Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241 [TBL] [Abstract][Full Text] [Related]
4. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578 [TBL] [Abstract][Full Text] [Related]
5. Solid histological component of adenocarcinoma might play an important role in PD-L1 expression of lung adenocarcinoma. Miyazawa T; Morikawa K; Otsubo K; Sakai H; Kimura H; Chosokabe M; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H Thorac Cancer; 2022 Jan; 13(1):24-30. PubMed ID: 34811933 [TBL] [Abstract][Full Text] [Related]
6. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study. Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075 [TBL] [Abstract][Full Text] [Related]
8. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Cancer Immunol Immunother; 2021 Apr; 70(4):1063-1074. PubMed ID: 33113005 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Chen YB; Mu CY; Huang JA Tumori; 2012 Nov; 98(6):751-5. PubMed ID: 23389362 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value. Farkašová A; Tancoš V; Kviatkovská Z; Huťka Z; Mičák J; Scheerová K; Szépe P; Plank L Cesk Patol; 2018; 54(3):137-142. PubMed ID: 30445818 [TBL] [Abstract][Full Text] [Related]
11. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer. Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750 [TBL] [Abstract][Full Text] [Related]
15. Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer. Nagasaki Y; Taki T; Nomura K; Tane K; Miyoshi T; Samejima J; Aokage K; Ohtani-Kim SJ; Kojima M; Sakashita S; Sakamoto N; Ishikawa S; Suzuki K; Tsuboi M; Ishii G J Natl Cancer Inst; 2024 Jul; 116(7):1158-1168. PubMed ID: 38459590 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung. Kim M; Chung YS; Kim KA; Shim HS Lung Cancer; 2019 Nov; 137():129-135. PubMed ID: 31586770 [TBL] [Abstract][Full Text] [Related]
17. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. Sun JM; Zhou W; Choi YL; Choi SJ; Kim SE; Wang Z; Dolled-Filhart M; Emancipator K; Wu D; Weiner R; Frisman D; Kim HK; Choi YS; Shim YM; Kim J J Thorac Oncol; 2016 Jul; 11(7):1003-11. PubMed ID: 27103510 [TBL] [Abstract][Full Text] [Related]
19. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153 [TBL] [Abstract][Full Text] [Related]
20. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas. Coppock JD; Volaric AK; Mills AM; Gru AA Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]